Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

Inclusion Criteria:

• Participants with a diagnosis of moderate to severe Ulcerative Colitis (UC)commenced on Risankizumab (RZB) treatment prescribed as part of their routineclinical care at their clinical's discretion according to Japan approved label andtreatment prescription recommendations/guidelines.

• The decision to prescribe RZB is made prior to and independently of studyparticipation.

• Participants able to provide voluntary informed consent before any study-relatedactivities or procedures (obtained/documented as per regulations). If the patient isunder 18 years old, a patient's parent or legal guardian must be willing to givewritten informed consent.

• Participants who can understand and communicate with the investigator and complywith the requirements of the study, including collection of PRO data using a smartdevice (i.e., mobile phone) and continued PRO data collection after cessation ofRZB.

• Participants without previous exposure to RZB.

• Participants who are not currently participating in interventional research (notincluding non-interventional studies, PMOS, or registry participation).

Exclusion Criteria:

See Inclusion Criteria